Defensin HD-5 Research: What 263 Studies Show (2026) | RetatrutideCompare

Defensin HD-5 — 263 studies indexed on PubMed. Cationic β-sheet peptide that disrupts microbial membranes and modulates intestinal microbiota. Half-life: Minutes systemically; concentrated in gut. FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Defensin HD-5?

There are approximately 263 studies indexed on PubMed that mention Defensin HD-5 (Human α-Defensin 5, DEFA5), based on a search last updated 2026-06-18.

Is Defensin HD-5 FDA-approved?

FDA status: Not FDA-approved.

How does Defensin HD-5 work?

Cationic β-sheet peptide that disrupts microbial membranes and modulates intestinal microbiota.

Reference facts

Also known as: Human α-Defensin 5, DEFA5
Category: Antimicrobial
Mechanism of action: Cationic β-sheet peptide that disrupts microbial membranes and modulates intestinal microbiota.
Targets: Microbial membranes, Intestinal innate immunity
Indications under research or approved: Research
Regulatory status (reference entry): Not FDA-approved
Half-life: Minutes systemically; concentrated in gut
Sequence: ATCYCRTGRCATRESLSGVCEISGRLYRLCCR
Sequence notes: 32-residue α-defensin from human Paneth cells; three intramolecular disulfide bonds.
Molecular weight (Da): 3582
PDB accession: 1ZMP
First reported: 1992

Primary References

Selsted & Ouellette, Nat Immunol 2005 (Defensins)

Explore research articles about Defensin HD-5

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.